Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease

Míreanna Comhchosúla

• Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
  le: Nirmala, Nanguneri, et al.
  Foilsithe: (2015)
• Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
  le: Kedor, Claudia, et al.
  Foilsithe: (2020)
• Therapy with canakinumab for adult-onset still's disease
  le: E. L. Nasonov
  Foilsithe: (2019-04-01)
• Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA
  le: Verweyen, Emely L, et al.
  Foilsithe: (2021)
• Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
  le: Galozzi, Paola, et al.
  Foilsithe: (2018)